miR-21 Is a Promising Novel Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer

Table 1

Relationship between clinicopathological factors and miR-21 expression in patients with GC.

Parameters	miR-21 expression		𝑃 value^*
	Low (𝑛=56)	High (𝑛=30)
Age (means ± SD, years)	56.03 ± 12.86	56.26 ± 11.14	0.436
Gender			0.128
Male	35 (62.3%)	20 (66.1%)
Female	21 (37.7%)	10 (33.9%)
Tumor location			0.526
Proximal	3 (5%)	1 (3%)
Body	24 (42.6%)	12 (41%)
Distal	28 (50.4%)	17 (56%)
Histologic type			<0.001
Differentiated	19 (34.3%)	7 (22.5%)
Undifferentiated	37 (65.7%)	23 (77.5%)
T stage			<0.001
T1	37 (66.7%)	15 (49.3%)
T2	12 (21.4%)	7 (23.6%)
T3	7 (11.9%)	5 (18.1%)
T4	0 (0%)	3 (9%)
Lymph node metastasis			<0.001
Present	17 (30.5%)	26 (85.3%)
Absent	39 (69.5%)	4 (14.7%)
Liver metastasis			0.266
Present	27 (47.8%)	15 (50.3%)
Absent	29 (52.2%)	15 (49.7%)
Peritoneal metastasis			0.137
Present	32 (57.8%)	18 (61.2%)
Absent	24 (42.2%)	12 (38.8%)
pTNM stage			<0.05
I	29 (52.6%)	12 (41.1%)
II	16 (27.8%)	7 (21.8%)
III	6 (11.3%)	6 (19.3%)
IV	5 (8.3%)	5 (17.8%)

^∗𝑃 value was tested in univariate analysis.